Skip to main navigation Skip to search Skip to main content

CAG expansion induces nucleolar stress in polyglutamine diseases

    Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

    Abstract

    The cell nucleus is amajor site for polyglutamine (polyQ) toxicity, but the underlying mechanisms involved have yet been fully elucidated. Here, we report that mutant RNAs that carry an expanded CAG repeat (expanded CAG RNAs) induce apoptosis by activating the nucleolar stress pathway in both polyQ patients and transgenic animal disease models. We showed that expanded CAG RNAs interacted directly with nucleolin (NCL), a protein that regulates rRNA transcription. Such RNA-protein interaction deprived NCL of binding to upstream control element (UCE) of the rRNA promoter, which resulted in UCE DNA hypermethylation and subsequently perturbation of rRNA transcription. The down-regulation of rRNA transcription induced nucleolar stress and provoked apoptosis by promoting physical interaction between ribosomal proteins and MDM2. Consequently, p53 protein was found to be stabilized in cells and became concentrated in the mitochondria. Finally, we showed that mitochondrial p53 disrupted the interaction between the antiapoptotic protein, Bcl-xL, and the proapoptotic protein, Bak, which then caused cytochrome c release and caspase activation. Our work provides in vivo evidence that expanded CAG RNAs trigger nucleolar stress and induce apoptosis via p53 and describes a polyQ pathogenic mechanism that involves the nucleolus.
    Original languageEnglish
    Pages (from-to)13428-13433
    JournalPNAS: Proceedings of the National Academy of Sciences of the United States of America
    Volume109
    Issue number33
    DOIs
    Publication statusPublished - 14 Aug 2012

    Research Keywords

    • Drosophila
    • Machado-Joseph disease
    • Rna toxicity
    • Spinocerebellar ataxia

    Fingerprint

    Dive into the research topics of 'CAG expansion induces nucleolar stress in polyglutamine diseases'. Together they form a unique fingerprint.

    Cite this